Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

Study Identifier
M02-516
CT.gov Identifier
NCT00062699
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Kidney Disease
    • Study Drug
  • Zemplar (paricalcitol injection)
  • Calcijex
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    20+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Stage V Chronic Kidney Disease Patients on Hemodialysis requiring treatment for secondary hyperparathyroidism with vitamin D therapy

    Protocol Summary

    To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for

    the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney

    disease on hemodialysis as measured by time to death.

    Study Locations

    Location
    Status
    Location
    Tuscaloosa Nephrology Associates
    Tuscaloosa, Alabama, United States, 35476
    Status
    Not applicable
    Location
    Gambro Healthcare - Inglewood
    Inglewood, California, United States, 90301
    Status
    Not applicable
    Location
    Gambro Healthcare - Los Angeles
    Los Angeles, California, United States, 90059
    Status
    Not applicable
    Location
    Apex Research of Riverside
    Riverside, California, United States, 92501
    Status
    Not applicable
    Location
    East Bay Nephrology Medical Group
    San Pablo, California, United States, 94806
    Status
    Not applicable
    Location
    Nephrology Educational Services and Research, Inc.
    Tarzana, California, United States, 91356
    Status
    Not applicable
    Showing {first} - {last} of {total} Results